Prognostic value of the ABCD2 clinical prediction rule: a systematic review and meta-analysis by Galvin, Rose et al.
Royal College of Surgeons in Ireland
e-publications@RCSI
General Practice Articles Department of General Practice
1-1-2011
Prognostic value of the ABCD2 clinical prediction
rule: a systematic review and meta-analysis
Rose Galvin
Royal College of Surgeons in Ireland, rosegalvin@rcsi.ie
Colm Geraghty
Royal College of Surgeons in Ireland
Nicola Motterlini
Royal College of Surgeons in Ireland
Borislav D. Dimitrov
Royal College of Surgeons in Ireland, borislav.d.dimitrov@gmail.com
Tom Fahey
Royal College of Surgeons in Ireland
This Article is brought to you for free and open access by the Department
of General Practice at e-publications@RCSI. It has been accepted for
inclusion in General Practice Articles by an authorized administrator of e-
publications@RCSI. For more information, please contact epubs@rcsi.ie.
Citation
Galvin R, Geraghty C, Motterlini N, Dimitrov BD, Fahey T. Prognostic value of the ABCD2 clinical prediction rule: a systematic
review and meta-analysis. Family Practice. 2010;0:1-11.
— Use Licence —
Attribution-Non-Commercial-ShareAlike 1.0
You are free:
• to copy, distribute, display, and perform the work.
• to make derivative works.
Under the following conditions:
• Attribution — You must give the original author credit.
• Non-Commercial — You may not use this work for commercial purposes.
• Share Alike — If you alter, transform, or build upon this work, you may distribute the resulting work only
under a licence identical to this one.
For any reuse or distribution, you must make clear to others the licence terms of this work. Any of these
conditions can be waived if you get permission from the author.
Your fair use and other rights are in no way affected by the above.
This work is licenced under the Creative Commons Attribution-Non-Commercial-ShareAlike License. To
view a copy of this licence, visit:
URL (human-readable summary):
• http://creativecommons.org/licenses/by-nc-sa/1.0/
URL (legal code):
• http://creativecommons.org/worldwide/uk/translated-license
This article is available at e-publications@RCSI: http://epubs.rcsi.ie/gpart/7
1 
 
Prognostic value of the ABCD2 clinical prediction rule: a systematic review and meta-
analysis  
 
Authors 
Rose Galvin, PhD 
Colm Geraghty, MB BCh BAO, MRCPI 
Nicola Motterlini, Stat.Sci.D 
Borislav D. Dimitrov, MD MSc SMHM DM/PhD 
Tom Fahey, MSc MD FRCGP 
 
Author affiliations 
HRB Centre for Primary Care Research, Department of General Practice, Royal College of 
Surgeons in Ireland, 123 St. Stephens Green, Dublin 2, Republic of Ireland.   
 
*Corresponding author  
Dr. Rose Galvin, HRB Centre for Primary Care Research, Department of General Practice, 
Royal College of Surgeons in Ireland, 123 St. Stephens Green, Dublin 2, Republic of Ireland.   
Tel: + 353 1 402 2305, Fax: +353 1 402 2137, Email: rosegalvin@rcsi.ie  
 
Funding sources 
This work was supported by the Noel Hickey Research Bursary 2010 in conjunction with the 
Irish Heart Foundation and also by the Health Research Board (HRB) of Ireland through 
the HRB Centre for Primary Care Research under Grant HRC/2007/1. 
2 
 
Word count: abstract 250, text 2862 
Number of tables: 5 
Number of figures: 4 
Number of appendices: 2
3 
 
Abstract  
Purpose: The ABCD2 clinical prediction rule (CPR) is designed to predict early risk of 
stroke after transient ischaemic attack (TIA). The purpose of this systematic review with 
meta-analysis is to determine the predictive value of the ABCD2 at 7 and 90 days across 
three strata of risk.  
 
Methods: A systematic literature search was conducted to identify studies that validated the 
ABCD2. The derived rule was used as a predictive model and applied to subsequent 
validation studies. Comparisons were made between observed and predicted number of 
strokes stratified by risk group, low (0-3 points), moderate (4-5 points) and high (6-7 points). 
Pooled results are presented as risk ratios (RRs) with 95% confidence intervals, in terms of 
over-prediction (RR>1) or under-prediction (RR<1) of stroke at 7 and 90 days.  
 
Results: We include 16 validation studies. Fourteen studies report 7 day stroke risk 
(n=6282, 388 strokes). The ABCD2 rule correctly predicts occurrence of  stroke at 7 days 
across all three risk strata: low, (RR 0.86, 95%CI(0.47-1.58), I2=16%); moderate, (RR 0.99, 
95%CI(0.67-1.47), I2=68%); high, (RR 0.84, 95%CI(0.6-1.19), I2=46%). Eleven studies 
report 90 day stroke risk (n=6304). There is a non-significant trend towards over prediction 
of  stroke in all risk categories at 90 days. There are 426 strokes observed in contrast to a 
predicted 626 strokes. As the trichotomised ABCD2 score increases, the risk of stroke 
increases (p<0.01). There is no evidence of publication bias in these studies (p>0.05). 
 
Conclusion: The ABCD2 is a useful CPR, particularly in relation to 7 day risk of stroke.  
 
4 
 
Keywords: stroke, TIA, transient ischaemic attack, risk prediction, ABCD2 
5 
 
Introduction 
The incidence of transient ischaemic attack (TIA) in the United States is estimated to be in 
the region of 200,000-500,000 per year.1 TIA and thrombotic stroke arise from identical 
aetiologies and a number of studies show that TIAs carry a significant risk of stroke.2-4 The 
burden of stroke lies with its long term disability, therefore prevention of stroke in 
individuals with TIA could significantly reduce the overall incidence and burden of stroke. 
Many patients with TIA do not receive timely assessment or management and the challenge 
to clinicians is to identify those who require urgent evaluation and treatment. Two clinical 
prediction rules, the ABCD system and the California rule,5-6 were developed to assist 
clinicians to quantify the short term risk of stroke after TIA. In 2007, these scores were 
unified and refined to form the ABCD2 rule.7  
 
The ABCD2 system is designed to assist clinicians with the timely and appropriate 
management of individuals with TIA and also to target secondary prevention and inform 
public education.8 The ABCD2 rule is a 7 point summation of clinical factors independently 
predictive of stroke risk. These factors include age, clinical features such as motor 
impairments and speech disturbance, duration of symptoms, history of diabetes and 
hypertension. A summary of the rule is contained in Figure 1. The developers originally 
identified three strata of stroke risk after TIA according to ABCD2 score; low (0-3 points), 
moderate (4-5 points) and high (6-7 points).7 The ABCD2 rule has been recommended for 
use in several national guidelines and management strategies based on the different 
guidelines are contained in Table 1.9-12   
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A number of studies have validated the ABCD2 rule in different populations and recent 
systematic review reported that the overall 7 day predictive value of the ABCD2 rule was 
high, resulting in predictive values ranging from 0.63 to 0.80 as the area under the receiver 
operating characteristic (ROC) curve at 7 days.8 However, CPRs are designed to be applied 
in a clinically meaningful way in terms of assisting clinicians with correct diagnosis and 
management of patients. The aim of this study is to examine the predictive value of the 
ABCD2 rule at 7 and 90 days using the original derivation study as a predictive model against 
which all subsequent validation studies are compared across three strata of risk, low (0-3 
points), moderate (4-5 points) and high (6-7 points). Therefore, the absolute risk of stroke is 
presented in three risk strata so that the value of the ABCD2 can be interpreted by clinicians. 
Our study aims to provide added clinical value to the findings of the previous review by 
presenting the results as trichotomised risk scores and not an aggregate measurement as with 
the ROC curve. We also examine internal and external sources of bias in the studies, 
including publication bias.  
 
INCLUDE TABLE 1 AND FIGURE 1 HERE 
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Methods 
Search strategy 
The PRISMA guidelines for the reporting of systematic reviews and meta-analyses were 
followed to conduct this review.13 We aimed to identify all studies of that validated the 
ABCD2 rule irrespective of setting or study design. A literature search was conducted in July 
2010 and included the following search engines: the Cochrane Library, EMBASE, Science 
Direct and PubMed. The databases were searched using a combination of the following 
keywords and MeSH terms: ‘transient ischaemic attack’ OR ‘TIA’ AND ‘cerebrovascular 
accident’ OR ‘CVA’ OR ‘stroke’ AND ‘score’ OR ‘prediction’ OR ‘prognosis’ OR ‘risk’. The 
search was supplemented by hand searching references of retrieved articles and searching 
Google Scholar. No restrictions were placed on language.  
 
Study selection and data extraction 
Studies were included if they met the following inclusion criteria; 1) Study design: 
prospective or retrospective cohort studies; 2) Patient population: adult patients (>18 years 
of age) with a diagnosis of TIA - TIA is defined as a sudden focal neurologic deficit lasting 
for less than 24 hours, of presumed vascular origin, and confined to an area of the brain or 
eye perfused by a specific artery;14 3) Explanatory variables: ABCD2 score calculated; 4) 
Setting of care: population and hospital based patients; and 5) Outcome measure: 
subsequent stroke at 7 or 90 days. The World Health Organization (WHO) define stroke as a 
clinical syndrome consisting of ‘rapidly developing clinical signs of focal (at times global) 
disturbance of cerebral function lasting more than 24 hours or leading to death with no 
apparent cause other than that of vascular origin’.15 Studies that included patients with minor 
stroke, where symptoms lasted more than 24 hours, were excluded from the analysis. Studies 
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that included the same data set for more than one publication were included once in the 
meta-analysis. Two reviewers (RG and CG) read the titles and/or abstracts of the identified 
references and eliminated irrelevant studies. Studies that were considered eligible for 
inclusion were read fully in duplicate and their suitability for inclusion to the study was 
independently determined by both CG and RG. Disagreements were managed by consensus. 
Additional data was sought from authors where necessary. Data was extracted on study 
design and setting, patient characteristics, method of data extraction and outcome at the 
follow-up time points. 
 
Validity Assessment 
Quality assessment was independently performed by two researchers (RG and CG) 
following the modified methodological standards of McGinn for validation studies of 
CPRs.16 The McGinn criteria examine the internal and external validity of studies in terms 
blinded assessment of predictor variables and outcome (stroke/no stroke), numbers 
followed up in the study (minimum ≥80%), methods of patient selection and spectrum of 
patients included with TIA.  
 
Statistical Methods 
The initial derivation study of the ABCD2 rule is used as a predictive model against which 
subsequent validation studies are compared. The results are presented in a clinically 
meaningful way across three different strata of risk. The number of strokes predicted across 
the three strata of risk - low risk (score 0-3), moderate risk (score 4-5) and high risk (score 6-
7) is compared with the observed number of strokes in each of the subsequent validation 
studies. Therefore the predicted number of patients with stroke at 7 and 90 days (based on 
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the probability calculated in the derivation study) is compared with the observed number of 
patients with stroke from each validation study. A sample of this calculation is contained in 
Table 2. A Chi-squared test for trend is computed to determine if there is an increasing trend 
in risk of stroke across the three ABCD2 risk categories. In addition, a 2x2 table is used to 
calculate sensitivities and specificities at the different dichotomised cut points of ≥3, ≥4 and 
≥5, as recommended in the national clinical guidelines (Table 1). We also examine the 
presence and extent of study effects or publication bias in the meta-analysis through the 
inspection of funnel plots.  
 
INSERT TABLE 2 HERE 
 
Review Manager 5 software from the Cochrane collaboration is used to perform the analysis, 
determine heterogeneity and produce forest plots. Results are presented as risk ratios (RR) 
with 95% confidence intervals using the Mantel-Haenszel statistical method. A RR score of  
1 represents accurate prediction by the ABCD2 rule, <1 represents under-prediction and >1 
over-prediction. A random effects analysis was applied and heterogeneity across the studies 
was quantified using the I2 statistic. If the I2 statistic was >50%, it was deemed that there was 
significant heterogeneity between the studies.   
 
10 
 
Results 
Study identification 
A flow diagram of the search strategy is presented in Figure 2. Two researchers screened all 
potential articles. The search strategy yielded 2481 papers of which 2425 publications were 
excluded based on their title or abstract. Sixteen of the remaining 56 studies met the 
inclusion criteria and were selected for analysis.7, 17-28 
 
Study description 
Table 3 summarises the characteristics of the included studies. Four cohorts are published by 
Oxford or California researchers.7 All publications are in English. Additional data was 
provided from six authors and clarification on methods of recruitment was sought from 
three authors. Four studies collected the ABCD2 data prospectively,20, 21, 23, 27 and twelve 
studies obtained the relevant information from patient notes retrospectively.7, 17-19, 22, 24-26, 28 
Eight studies were conducted in an Emergency Department,7, 17, 20, 23-27 three were TIA-clinic 
based,7, 28 two were population based,7, 22 and three were based in specialty stroke centres.18, 19, 
21 The included studies range in size from 87,20 to 1411 patients.25 A total of 8482 participants 
are included in the analysis.  
 
INSERT FIGURE 2 AND TABLE 3 HERE 
 
Study quality 
The methodological quality of the studies is detailed in Table 4. The external validity of the 
studies is good and the main shortcoming in relation to internal validity is with inadequate 
reporting of blinding in the included studies. There is no evidence of publication bias in the 
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studies included in the 7 day or 90 day analysis (p>0.05). See supplementary Appendices 1 
and 2 respectively.  
 
INSEERT TABLE 4 HERE  
 
7 day stroke risk 
Fourteen studies (n=6282) report 7 day risk of stroke.7, 17-24, 26, 27 The ABCD2 rule correctly 
predicts occurrence of  stroke at 7 days across all three risk strata: low risk (n=2153), 
moderate risk (n=2943) and high risk (n=1186). The results are displayed in Figure 3. There 
are 357 strokes predicted and 388 strokes observed at 7 days across all three risk strata. A 
subgroup analysis of  the two population based studies7, 22  including patients recruited from 
primary care settings indicates that the ABCD2 rule performs well on the low and moderate 
risk groups but significantly under predicts the risk of  stroke at 7 days in the high risk group 
(RR 0.48, 95% CI (0.27-0.88), I2=0%).  
 
The chi-squared analysis indicates that as the trichotomised ABCD2 score increases, the 
probability of stroke increases (p<0.01). The sensitivity and specificity of  the dichotomised 
cut points used to discriminate individuals at low and high risk of  stroke at 7 days, which 
have been utilised in different national clinical guidelines, are contained in Table 5. Our 
pooled data indicates that 9.5% of  the total strokes at 7 days occur in the low risk group, 
51% are observed in the moderate risk group and 39.5% of  the total strokes occur in the 
high risk group. 
 
INSERT TABLE 5 HERE 
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90 day stroke risk 
Eleven studies (n=6304) report 90 day risk of stroke.7, 19-21, 25-28 The ABCD2 rule tends to over 
predict the occurrence of  stroke across all three risk strata: low risk (n=2205), moderate risk 
(n=2869) and high risk (n=1230). The results are presented in Figure 4. There are 426 
strokes observed at 90 days in contrast to a predicted 626 strokes. The chi-squared analysis 
shows that as the trichotomised ABCD2 score increases, the risk of stroke increases 
(p<0.01).The sensitivity and specificity of  the cut points used to discriminate individuals at 
low and high risk of  stroke at 90 days are contained in Table 5. At 90 days, 13.6% of  all 
strokes observed occur in the low risk group, 50% occur in the moderate risk group and 
36.4% occur in the high risk group.  
 
INSERT FIGURES 3 AND 4 HERE
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Discussion 
Statement of  principal findings 
This systematic review shows that the ABCD2 clinical prediction rule correctly predicts the 
occurrence of  stroke at 7 days in individuals with TIA across all three strata of  risk. 
However, a subgroup analysis of  the population based studies indicates that the rule 
significantly under predicts the risk of  stroke in those classified as high risk.  At 90 days, the 
ABCD2 rule tends to over-predict occurrence of  stroke in the three risk categories. These 
results also show that the likelihood of  having a stroke increases as the ABCD2 
trichotomised score increases. 
 
Current context and future research directions  
A recent systematic review examines the discriminative ability of the ABCD system using 
summary ROC curves.8 Our method of calibration examines the predictive ability of the rule 
by using the ratio of predicted stroke (from the original derivation study) to observed stroke 
in the subsequent validation studies. The absolute risk of stroke is presented in risk strata so 
that the value of the ABCD2 across these strata can be interpreted in a clinically meaningful 
way. The method of analysis used to pool the individual ABCD2 validation studies is based 
on a comparative approach that extends and employs the absolute risk from the derivation 
study as a model to generate predicted values in subsequent validation studies. This statistical 
method is supported by an analysis that compares our method to a validated and published 
method for comparing predicted to observed values.29 No statistically significant difference 
(p>0.05) was found between the predicted events by the two methods (unpublished study). 
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Our results support the findings of  the previous review, suggesting that the ABCD2 rule is a 
good predictor of  stroke at 7 days and had been broadly validated in a wide variety of  
clinical settings. However, these is a need for future large multi-centre randomised controlled 
trials to examine the impact of applying the rule in different clinical settings, particularly in 
the primary care setting,  in terms of patient outcome, clinician behaviour, cost effectiveness 
and resource use, or any combination of these.30 
 
Strengths and weaknesses of the study 
Our systematic review pools data from 16 separate cohorts of  individuals with TIA. This 
facilitates an assessment of  the performance of  the ABCD2 rule across different clinical 
settings, addressing validity, applicability and precision of  estimates across three different 
strata of  risk. Sixteen ABCD2 validation studies are included in the previous review.8 Five of 
these studies pertain to unpublished data that is not included in our review. However, we 
include data on five additional studies.23, 25-28 We assess the predictive value of  the ABCD2 
score at 7 and 90 days. Some authors have validated the ABCD2 score at 2 days,7, 23, 26 and it is 
widely accepted that the risk of  stroke is greatest in the first 24 to 48 hours after TIA with 
up to half  of  all subsequent strokes occurring during this time.31 However, due to the 
variability in time from symptom onset between the studies, it was not possible to validate 
the score at 2 days following onset of  symptoms in this review. 
 
In spite of  its ability to accurately determine stroke risk and triage individuals accordingly, 
clinical use of  the ABCD2 rule has some limitations. There is significant heterogeneity in the 
ABCD2 calibration analysis (I2=16%-68% at 7days and 46%-86% at 90 days). Heterogeneity 
in the studies could be due to a variety of factors. Firstly, study setting and time from onset 
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of  symptoms to clinical assessment varies across studies and the clinical diagnosis of  TIA is 
not performed by a neurologist in all studies. Secondly, methodological quality of  the studies 
needs to be considered. Seven studies do not report if  the individual assessing stroke 
outcome is blinded to the presence of  predictors, such as the components of  the ABCD2 
rule. Therefore the diagnosis of  stroke may be modified by knowledge of  another reference 
standard such as imaging. However, all studies report that the WHO definition of  stroke was 
used to define stroke outcome.  
 
Clinical and policy implications 
Current international guidelines recommend that individuals with low ABCD2 scores should 
be triaged for specialist assessment within one week of  onset of  symptoms. Approximately 
one third of  individuals in our pooled data are in the low risk category and a significant 
minority of  strokes (9.5%) occur in this patient group within 7 days. Therefore it is 
important that these ‘low risk’ individuals receive timely treatment to minimise the risk of  
subsequent stroke. In the hospital setting, imaging evidence of carotid stenosis or DWI 
abnormality may also serve to assist in the identification of patients at high early risk of 
stroke after TIA.32 In terms of  implementing the rule in general practice, clinicians need to 
exert caution when applying the rule as it has only been validated in two population based 
cohorts. However, the rule does serve to quantify the contribution of  the patient’s history 
and physical examination to stratify them according to their risk of  developing a subsequent 
stroke.  
 
National guidelines relating to the management of individuals classified as ‘high risk’ include 
early neurology consultation to confirm the diagnosis of TIA, rapid diagnostic assessment, 
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and implementation of aetiology-specific precautionary measures, including carotid 
endarterectomy and anticoagulation. However, there is a need for consensus in relation to 
the identification of individuals at high risk of subsequent stroke. The different cut-points 
used in the guidelines to categorise stroke risk have considerable economic and management 
implications. The developers identify three strata of stroke risk after TIA according to 
ABCD2 rule and we have analysed our data accordingly.  However, international consensus 
on what constitutes a ‘low’ and ‘high’ risk patient would serve to improve care, reduce 
variability, and reduce costs and burden of disease, particularly when evidence is evolving 
rapidly. 
 
Conclusion 
The results of this pooled analysis confirm the ability of the ABCD2 score to correctly 
predict short term risk of stroke after TIA and also to separate those at lowest, moderate and 
highest risk of stroke across a wide range of populations and clinical settings. In spite of its 
limitations, the ABCD2 is easy and quick to administer and it is a useful tool to assist 
clinicians in the management of individuals with TIA.  
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Table 1: Guidelines on the management implications of ABCD2 score in the low and high risk groups 
National Guidelines High Stroke Risk  Low Stroke Risk  
NICE - UK Guidelines ABCD2 score ≥ 4 ABCD2 score < 4 
Assessment Specialist assessment within 24 hours of onset 
of symptoms 
Specialist assessment as soon as possible, but 
definitely within 1 week of onset of symptoms 
Imaging Urgent brain imaging (preferably DWMRI)  
(‘urgent’ is considered within 24 hours of 
symptom onset) 
Brain imaging within 1 week of onset of 
symptoms 
New Zealand Guidelines ABCD2 score ≥ 4 ABCD2 score < 4 
Assessment  Specialist assessment within 24 hours of onset 
of symptoms 
Specialist assessment as soon as possible, but 
definitely within 1 week of onset of symptoms 
Imaging  Urgent MRI or CT brain (‘urgent’ is considered 
as soon as possible, but certainly within 24 
hours) 
MRI or CT brain as soon as possible, but 
certainly within 7 days 
Australian Guidelines ABCD2 score ≥ 5 ABCD2 score < 5 
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Assessment  Admitted to a stroke unit (or where available 
referred to a specialist TIA clinic where the 
person can be assessed within 24-48 hours) to 
facilitate rapid assessment and treatment 
Managed in the community by a GP, private 
specialist or where possible referred to a 
specialist TIA clinic and seen within 7-10 days  
Imaging  Urgent CT brain (‘urgent’ is considered as soon 
as possible, but certainly within 24 hours).  
CT brain and carotid ultrasound (where 
indicated) as soon as possible (i.e. within 48-72 
hours). 
US Guidelines ABCD2 score ≥ 3 ABCD2 score < 3 
Assessment Admission to hospital for specialist assessment 
and treatment as soon as possible after the event 
Admission to hospital if there is uncertainty that 
diagnostic workup can be completed within 2 
days as an outpatient 
Imaging Undergo neuroimaging evaluation within 24 
hours of symptom onset (preferably DWMRI, 
otherwise CT brain) 
Undergo neuroimaging evaluation within 24 
hours of symptom onset (preferably DWMRI, 
otherwise CT brain) 
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Table 2: Calculation of 7 day stroke risk using derivation study as a predictive model 
DERIVATION STUDY7 
ABCD2 risk stratification Group (n) Strokes observed (n) Strokes observed (%) 
Low Risk 520 7 1.35 
Intermediate risk 921 60 6.51 
High risk 469 53 11.3 
 
VALIDATION STUDY27 
ABCD2 risk stratification Group (n) Strokes predicted (%)* Strokes predicted (n)* Strokes observed (n)** 
Low Risk 71 1.35 1 2 
Intermediate risk 56 6.51 4 5 
High risk 21 11.3 2 5 
*using original derivation study as a predictive model, ** actual number of strokes reported in each strata of risk 
Note: The existing derivation/prognostic model (that is, both the selected variables and their coefficients) is used to predict outcomes for 
the patients in the validation dataset. The patients’ actual outcome (stroke/no stroke) is then compared this prediction. This analysis uses 
each individual’s event probability calculated from their risk score from the original model. 
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Table 3: Characteristics of studies included in the review 
Authors Study setting Study type Participants: n, 
age, sex 
Definition of 
TIA* 
Time from 
onset of 
symptoms 
Outcomes 
reported 
Johnson et al 
2007  
(California ED) 
Hospital based Retrospective 
validation of 
prospective 
consecutive cohort 
n=1069, 510 males, 
559 females 
Classic <24 hours in 
99% of 
admissions 
Stroke at 2 days 
Stroke at 7 days 
Stroke at 90 days 
Johnson et al 
2007  
(California Clinic) 
Hospital based Retrospective 
validation of 
prospective 
consecutive cohort 
n=962, 455 males, 
507 females 
Classic < 1 week  Stroke at 2 days 
Stroke at 7 days 
Stroke at 90 days 
Johnson et al 
2007  
(Oxford 
Population 
based** 
Retrospective 
validation of 
prospective 
***n=547, 247 
males, 300 females 
Classic ‘assessed as 
soon as 
possible after 
Stroke at 2 days 
Stroke at 7 days 
Stroke at 90 days 
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Population) consecutive cohort the event’  
Johnson et al 
2007  
(Oxford Clinic) 
Hospital based Retrospective 
validation of 
prospective 
consecutive cohort 
n=315, 144 males, 
171 females 
Classic ‘assessed as 
soon as 
possible after 
the event’ 
Stroke at 2 days 
Stroke at 7 days 
Stroke at 90 days 
 
Tsivgoulis et al 
2007 
Hospital based Retrospective 
validation of 
consecutive 
admissions using 
medical charts 
n=226, 133 males, 
93 females  
mean age 63.9 
years 
Classic <48 hours  Stroke at 7 days 
Stroke at 30 days 
Coutts et al 2008 Hospital based Prospective 
consecutive cohort 
n=87 Classic < 12 hours Stroke at 30  
Stroke at 90 days 
Asimos et al 
2009 
Hospital based Retrospective 
validation of non-
consecutive 
†n=1667, 754 
males, 913 females 
mean age 67.4 
Classic < 24 hours Stroke at 7 days 
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admissions using 
medical charts 
years 
Ay et al 2009 Hospital based Retrospective 
validation of 
consecutive 
admissions using 
medical charts 
n=477, 231 males, 
246 females,  
mean age 67.7 
years 
Classic < 24 hours Stroke at 7 days 
Calvet et al 2009 Hospital based Retrospective 
validation of 
prospective 
consecutive cohort 
n=343, 212 males, 
131 females 
mean age 62.4 
years 
Classic < 48 hours Stroke at 7 days  
Stroke at 3 
months 
Cucchiara et al 
2009 
Hospital based Prospective 
consecutive cohort  
 n=167, 75 males, 
92 females  
mean age 62 years 
 
Classic < 48 hours Stroke at 90 days 
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Fothergill et al 
2009 
Population 
based** 
Retrospective 
validation of 
consecutive 
admissions using 
medical charts 
n=284, 126 males, 
158 females  
mean age 71.9 
years 
Classic  < 72 hours  Stroke at 7 days 
Stroke at 30 days 
Stroke at 365 days 
Song et al 2009 Hospital based Prospective 
consecutive cohort 
n=136  Classic < 48 hours Stroke at 2 days 
Stroke at 7 days 
Weimar et al 
2009 
Hospital based Retrospective 
validation of 
prospective 
consecutive cohort 
††n=1448, 778 
males, 670 females 
mean age 67.6 
years 
Classic <24 hours in 
91.9% of 
admissions 
Stroke at 90 days 
Ong et al 2010 Hospital based Retrospective 
validation of 
consecutive 
admissions using 
n=470, 293 males, 
177 females 
mean age 61 years 
Classic Unreported Stroke at 2 days 
Stroke at 7 days 
Stroke at 30 days 
Stroke at 90 days 
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computerised 
medical charts 
Tsivgoulis et al 
2010 
Hospital based Prospective 
consecutive cohort 
n=148, 82 males, 
66 females 
mean age 60 years 
Classic Unreported Stroke at 7 days 
Stroke at 90 days 
 
Harrison et al 
2010 
Hospital based Retrospective 
validation of 
prospective 
consecutive cohort 
‡n=795, 342 males, 
453 females 
mean age 67 years 
Classic  Unreported  Stroke at 90 days 
Stroke at 1 year 
Stroke at 5 years 
Stroke at 10 years 
* Classic definition of TIA – ‘A sudden focal neurologic deficit lasting less than 24 hours, of presumed vascular origin, and confined to an 
area of the brain or eye perfused by a specific artery’14 
**Population based – participants were recruited from general practice, outpatient clinics and hospital settings 
***data analysed in 543 individuals only 
†data was analysed in 1054 individuals only 
††data was analysed in 1411 individuals only  
‡data was analysed in 789 individuals only 
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Table 4: Methodological quality of studies included in the review (McGinn Criteria) 
 
Were those assessing 
the outcome event 
blinded to presence 
of predictors? 
Were those assessing 
the presence of 
predictors blinded to 
the outcome event? 
Was there 
≥80% follow up 
of those 
enrolled? 
Were patients 
selected in an 
unbiased 
fashion? 
Do patients 
represent a wide 
spectrum of 
severity of disease? 
Johnson et al 2007 
(California ED) Unreported Yes Unreported Yes Yes 
Johnson et al 2007 
(California clinic) Unreported Yes Unreported Yes No 
Johnson et al 2007 
(Oxford population) Unreported Yes Yes Yes Yes 
Johnson et al 2007 
(Oxford clinic) Unreported Yes Unreported Unreported Yes 
Tsivgoulis et al 2007 Unreported Yes Yes Yes Yes 
Coutts et al 2008 Unreported Yes Unreported Yes Yes 
Asimos et al 2009 Yes No No No No 
Ay et al 2009 Yes Unreported No Yes Yes 
Calvet et al 2009 Yes Yes Yes Yes Yes 
Cucchiara et al 2009 Yes Yes Yes Unreported Yes 
Fothergill et al 2009 Unreported Yes Yes Yes Yes 
Song et al 2009 Unreported Yes Yes Yes Unreported 
Weimar et al 2009 Unreported Unreported Yes Yes Yes 
Ong et al 2010 Unreported Unreported Yes Yes Yes 
Tsivgoulis et al 2010 Yes Yes Yes Yes Yes 
Harrison et al 2010 Unreported Unreported Yes Yes No 
 
31 
 
 
Table 5: Sensitivity and specificity conventional ABCD2 score cut-off 
ABCD2 dichotomisation    
(as per international guidelines) 
Diagnostic accuracy (95% confidence interval) 
ABCD2 ≥3 Sensitivity Specificity Likelihood ratio (+) Positive predictive value  
7 days 0.96 (0.94-0.98) 0.17 (0.16-0.18) 1.16 (1.13-1.19) 7.4% (6.7-8.2%) 
90 days 0.94 (0.92-0.96) 0.17 (0.16-0.18) 1.14 (1.11-1.17) 7.8% (7.1-8.6%)  
ABCD2 ≥4     
7 days 0.90 (0.87-0.93) 0.36 (0.34-0.37) 1.40 (1.35-1.46) 8.8% (7.9-9.7%) 
90 days 0.86 (0.82-0.89) 0.36 (0.33-0.38) 1.35 (1.29-1.41) 9.1% (8.2-10%) 
ABCD2 ≥5     
7 days 0.70 (0.65-0.74) 0.60 (0.59-0.62) 1.77 (1.64-1.90) 10.9% (9.7-12.2% ) 
90 days 0.63 (0.58-0.68) 0.61 (0.59-0.62) 1.59 (1.47-1.73) 10.5% (9.3-11.8%) 
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Figure 1: Summary of the ABCD2 score 
Age -  ≥ 60 years (1 point) 
BP - systolic >140 mm Hg or diastolic >90 mm Hg (1 point) 
Clinical features - unilateral weakness (2 points), speech impairment without unilateral 
weakness (1 point) 
Duration of symptoms - ≥60 minutes (2 points), 10–59 minutes (1 point) 
Diabetes (1 point) 
  
0-3 points 4-5 points 6-7 points 
Low risk Moderate risk High risk 
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Figure 2: Search strategy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*One article contained data on 4 different cohorts 
Records identified through 
database searching  
(n=2574) 
Additional records identified 
through other sources  
(n=4) 
Records after duplicates removed  
(n=2481) 
Records screened  
(n=2481) 
Records excluded after reading title 
(1381)  
Records excluded after reading 
abstract (n=1044) 
Full-text articles assessed 
for eligibility  
(n=56) 
Articles included analysis  
(n=13)* 
Studies included analysis  
(n=16) 
 
Excluded (n=43) 
Used data from another study (n=11) 
ABCD2 score not applied (n=9) 
Stroke outcome not examined (n=7) 
Variability in time since TIA (n=6) 
Clinical data unpublished (n=5) 
No follow up reported (n=3) 
Assessment of outcome at different 
follow up time points (n=2) 
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Figure 3: Prediction of 7 day risk of stroke across the three risk strata 
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Figure 4: Prediction of 90 day risk of stroke across the three risk strata 
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Appendix 1: Funnel plot of studies included in the 7 day analysis 
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Appendix 2: Funnel plot of studies included in the 90 day analysis 
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